133 related articles for article (PubMed ID: 29962402)
1. Doxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice.
Emam SE; Ando H; Abu Lila AS; Kobayashi S; Shimizu T; Okuhira K; Ishima Y; Ishida T
Biol Pharm Bull; 2018; 41(7):1078-1083. PubMed ID: 29962402
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Hekmatirad S; Moloudizargari M; Moghadamnia AA; Kazemi S; Mohammadnia-Afrouzi M; Baeeri M; Moradkhani F; Asghari MH
Front Immunol; 2021; 12():692654. PubMed ID: 34149737
[TBL] [Abstract][Full Text] [Related]
3. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
5. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
6. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
8. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
9. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
11. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil
Takayama T; Shimizu T; Lila ASA; Kanazawa Y; Ando H; Ishima Y; Ishida T
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33086690
[TBL] [Abstract][Full Text] [Related]
13. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.
Hattori Y; Shibuya K; Kojima K; Miatmoko A; Kawano K; Ozaki K; Yonemochi E
Int J Oncol; 2015 Jul; 47(1):211-9. PubMed ID: 25955490
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis.
Qiu X; Li Z; Han X; Zhen L; Luo C; Liu M; Yu K; Ren Y
Theranostics; 2019; 9(9):2618-2636. PubMed ID: 31131057
[TBL] [Abstract][Full Text] [Related]
16. Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity.
Li W; Mu D; Tian F; Hu Y; Jiang T; Han Y; Chen J; Han G; Li X
Mol Med Rep; 2013 Dec; 8(6):1876-82. PubMed ID: 24146068
[TBL] [Abstract][Full Text] [Related]
17. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.
Khan FM; Saleh E; Alawadhi H; Harati R; Zimmermann WH; El-Awady R
Cancer Biol Ther; 2018 Jan; 19(1):25-33. PubMed ID: 29244610
[TBL] [Abstract][Full Text] [Related]
19. Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.
Wang J; Yeung BZ; Cui M; Peer CJ; Lu Z; Figg WD; Guillaume Wientjes M; Woo S; Au JL
J Control Release; 2017 Dec; 268():147-158. PubMed ID: 29054369
[TBL] [Abstract][Full Text] [Related]
20. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio.
Yang T; Martin P; Fogarty B; Brown A; Schurman K; Phipps R; Yin VP; Lockman P; Bai S
Pharm Res; 2015 Jun; 32(6):2003-14. PubMed ID: 25609010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]